Quantcast
Last updated on April 18, 2014 at 6:20 EDT

Latest Guerbet Stories

2014-04-10 12:28:09

Guerbet LLC, USA PRINCETON, N.J., April 10, 2014 /PRNewswire/ -- Guerbet, a pioneer in the field of contrast agents for medical imaging announced that Lipiodol® was approved by the US Food and Drug Administration pursuant to section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act indicated for selective hepatic intra-arterial use for imaging tumors in adults with known hepatocellular carcinoma (HCC). HCC is the most common primary liver tumor and represents the third-leading...

2014-03-24 08:28:31

PRINCETON, N.J., March 24, 2014 /PRNewswire/ -- Sirtex Medical Limited (ASX: SRX) and Guerbet S.A. (GBT.PA) are pleased to announce today that the two companies are entering into a collaboration to advance research in primary and secondary metastatic liver cancer. The objective of the collaboration is to evaluate the unmet clinical need in patients with hepatocellular carcinoma, metastatic colorectal cancer, neuroendocrine tumors, and a range of other secondary liver cancers*....

2014-02-19 16:23:53

PRINCETON, N.J., Feb. 19, 2014 /PRNewswire/ -- Guerbet (GBT), the contrast agent specialist for medical imaging, today announced that it had received approval from the U.S. Food and Drug Administration (FDA) for a new manufacturing plant for Lipiodol(®) (ethiodized oil) Injection, in Montreal, Canada. FDA approval provides clinicians with additional resource for patient care management. Guerbet has acquired the Ethiodol(® )NDA effective May 7, 2010 and since then has been working with the...

2013-11-26 23:00:43

Guebert announces largest exhibit presence ever at Radiology Society of North America Annual Meeting Princeton, NJ (PRWEB) November 26, 2013 Guerbet announced today that it will have the company’s largest exhibit presence ever at the Radiology Society of North America (RSNA)’s 99th Assembly and Annual Meeting Dec. 1-6 in Chicago. Guerbet will be exhibiting at Booth #2535 South Building, Hall A. This will mark the first RSNA for Guerbet since the U.S. Food and Drug Administration...

2013-11-06 12:28:56

PRINCETON, N.J., Nov. 6, 2013 /PRNewswire/ -- Guerbet announced today that Novation, the leading health care supply chain expertise, analytics and contracting company, has awarded a new agreement for Dotarem(®) (gadoterate meglumine) Injection, a gadolinium-based contrast agent (GBCA) indicated for intravenous use with magnetic resonance imaging (MRI) in brain (intracranial), spine and associated tissues in adult and pediatric patients (2 years of age and older) to detect and visualize...

2013-10-21 12:27:50

PRINCETON, N.J., Oct. 21, 2013 /PRNewswire/ -- Guerbet LLC, USA -- Guerbet, a pioneer in the field of contrast agents with more than 80 years of experience, announced that it has been granted Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development (OOPD) for Lipiodol (Ethiodized Oil) Injection for management of patients with known hepatocellular carcinoma (HCC). Hepatocellular carcinoma prevalence in US is estimated to...

2013-09-05 23:00:38

Guerbet announces first US adult injection of Dotarem (gadoterate meglumine) Princeton, NJ (PRWEB) September 05, 2013 Guerbet announced today that Winthrop-University Hospital in Mineola, NY recently performed the first US adult injection of Dotarem® (gadoterate meglumine), the only macrocyclic and ionic gadolinium-based contrast agent (GBCA) approved by the US Food and Drug Administration. The procedure was performed in an adult with borderline renal function. It follows the first...

2013-07-25 12:28:23

PRINCETON, N.J., July 25, 2013 /PRNewswire/ -- Guerbet announced today that Cincinnati Children's Hospital Medical Center (Cincinnati Children's) last week performed the first US injection of Dotarem(®) (gadoterate meglumine), the only macrocyclic and ionic gadolinium-based contrast agent (GBCA) approved by the US Food and Drug Administration. The procedure was performed in a school age child. Dotarem(®) is indicated for intravenous use with magnetic resonance imaging (MRI) in...

2013-03-21 12:27:27

VILLEPINTE, France, March 21, 2013 /PRNewswire/ -- Guerbet announced today that the US Food and Drug Administration (FDA) has approved Dotarem® (gadoterate meglumine), a gadolinium-based contrast agent (GBCA) indicated for intravenous use with magnetic resonance imaging (MRI) in brain (intracranial), spine and associated tissues in adult and pediatric patients (2 years of age and older) to detect and visualize areas with disruption of the blood brain barrier (BBB) and/or abnormal...

2013-02-14 16:25:28

VILLEPINTE, France, Feb. 14, 2013 /PRNewswire/ -- Guerbet, the contrast agent specialist for medical imaging, today announced that the Medical Imaging Drugs Advisory Committee to US Food and Drug Administration (FDA) has voted unanimously by votes of 17 to 0 to recommend that FDA approve the New Drug Application (NDA) for Dotarem® (gadoterate meglumine) for adults, and for pediatric use for children two years of age and older. The Committee voted 10 to 6 (with one member abstaining) not...